Drug intelligence / Profile preview

EV302

Development stage: Preclinical
Lead developer: Astellas Pharma
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

EV302 is a preclinical-stage therapeutic candidate being developed by EV Therapeutics for the treatment of gastric cancer. The drug is part of a pipeline focused on gastrointestinal (GI) malignancies and utilizes the company's proprietary extracellular vesicle (EV) platform. This platform leverages exosomes as delivery vehicles for therapeutic payloads, aiming to enhance targeting and reduce systemic toxicity compared to traditional delivery methods. As of early 2024, specific molecular targets and the nature of the therapeutic payload for EV302 remain undisclosed by the developer.

Beyond the preview

Go deeper on EV302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EV302.

Explore the full profile